Seelos Therapeutics, Inc.
SEEL · NASDAQ
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.36 | 33.40 | -3.84 | 5.70 |
| FCF Yield | -2.76% | -0.67% | -0.26% | -0.23% |
| EV / EBITDA | -23.23 | -125.87 | 0.00 | 0.00 |
| Quality | ||||
| ROIC | 210.04% | -767.35% | -82.62% | -151.06% |
| Gross Margin | -1,267.09% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.63 | 0.84 | 0.74 | 1.09 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | -100.00% | – |
| Free Cash Flow Growth | 61.18% | -25.74% | -134.28% | -8.33% |
| Safety | ||||
| Net Debt / EBITDA | -0.30 | -0.06 | 0.00 | 0.00 |
| Interest Coverage | -539.99 | -5,065.43 | -38.59 | -114.38 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -72.38 | -24,971.51 | 0.00 | 0.00 |